ORICORIC Pharmaceuticals, Inc.
$13.17+9.0% 1Y
$13.17
$7.4752 weeks$14.67
ORIC in its own filings
Nothing in ORIC's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
121
Events found in the filings · across 423 filings · the record starts in 2020
- Hard flags
- none
Hard flags
- Most recent filing
- Oct 23, 2026
Most recent filing · Form 8-K
- Record starts
- Jan 9, 2020
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 12, 2026
- SEC comment-letter activity19 occurrences
- 2025-06-17
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 23, 2026The Program Update covered updated data from the Company’s Phase 1b trial of enozertinib, as well as the Company’s plans to initiate a global Phase 3 registrational trial of enozertinib in the first half of 2027: Enozertinib Phase 1b Data in 1L EGFR Atypical NSCLC Enozertinib is being evaluated in an ongoing Phase 1b …Regulation FD disclosure · Form 8-K
- Aug 3, 2026ORIC ® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates.Earnings release · press release
- Jul 30, 2026Effective July 28, 2026, the Board of Directors (the “Board”) of ORIC Pharmaceuticals, Inc. (the “Company”) approved the ORIC Pharmaceuticals, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan (as amended, the “Inducement Plan”), in order to increase the number of shares reserved for issuance under the …Director or officer change · Form 8-K
- Jun 22, 2026ORIC Pharmaceuticals, Inc. (the “Company”) amended and restated its 2020 Equity Incentive Plan (the “A&R 2020 Equity Incentive Plan”), effective as of June 18, 2026 upon approval by the stockholders of the Company at the Annual Meeting (as defined below)Director or officer change · Form 8-K
- May 4, 2026ORIC ® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates.Earnings release · press release
- Mar 31, 2026ORIC Pharmaceuticals, Inc. (the “Company”) presented a rinzimetostat (ORIC-944) program update (the “Program Update”) on March 31, 2026. The Program Update covered recently announced dose optimization data from the Company’s Phase 1b trial of rinzimetostat.Other event · Form 8-K
- Feb 23, 2026On May 6, 2021, ORIC Pharmaceuticals, Inc. (the “Company”) entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”) to sell shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), from time to time, through an “at the market offering” program …Other event · Form 8-K
- Feb 23, 2026ORIC ® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates.Earnings release · press release
- Dec 8, 2025ORIC Pharmaceuticals, Inc. (the “Company”) presented an enozertinib (ORIC-114) program update (the “Program Update”) on December 6, 2025. The Program Update covered recently announced data from the Company’s Phase 1b trial of enozertinib.Other event · Form 8-K
- Nov 13, 2025ORIC-944 Dose Exploration Data Update.Regulation FD disclosure · press release
- Nov 13, 2025ORIC ® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…